Drug Profile
Cetuximab biosimilar - PlantForm Corporation
Latest Information Update: 01 Jan 2022
Price :
$50
*
At a glance
- Originator PlantForm Corporation
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Canada (Parenteral)
- 18 Sep 2013 Cetuximab biosimilar - PlantForm Corporation is available for licensing as of 17 Apr 2013. http://www.plantformcorp.com/
- 30 Sep 2012 Preclinical trials in Head and neck cancer in Canada (Parenteral)